DCGI approves Themis Medicare's Viralex for Covid-19 treatment
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage that can potentially prevent viral entry, regardless of vaccination or infection status
Leaders in scientific and industrial imaging, Atik Cameras prepares for growth as Dr Panos Kapetanopoulos is promoted to DIrector of Atik Cameras Norwich, UK
The Omicron variant doesn't escape RTPCR and RAT; States advised to ramp up testing for prompt and early identification of any cases
This is a shot in the arm for the vaccine manufacturers
Evidence also shows better immune response to virus among users of spray
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Godrej and Boyce and Isgec Engineering have confirmed receiving the orders
Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
Subscribe To Our Newsletter & Stay Updated